US Patent

US11426416 — Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same

Method of Use · Assigned to Clarus Therapeutics Inc · Expires 2030-04-12 · 4y remaining

Vulnerability score 76/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a pharmaceutical formulation of testosterone undecanoate and methods of treating testosterone deficiency or its symptoms with this formulation.

USPTO Abstract

A pharmaceutical formulation of testosterone undecanoate is provided. Methods of treating a testosterone deficiency or its symptoms with the inventive formulations are also provided.

Drugs covered by this patent

Aveed (TESTOSTERONE UNDECANOATE) · Marius

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3420`	—	Aveed
`U-3420`	—	Aveed
`U-3420`	—	Aveed

Patent Metadata

Patent number: US11426416
Jurisdiction: US
Classification: Method of Use
Expires: 2030-04-12
Drug substance claim: No
Drug product claim: No
Assignee: Clarus Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.